MYD88 and metabolic dysfunction-associated steatotic liver disease: Liu et al. demonstrated that AsIV significantly alleviated hepatic steatosis, reduced lipid droplet accumulation in hepatocytes, and improved liver injury in NAFLD rats through inhibition of the TLR4/myeloid differentiation primary response 88 (MyD88)/NF-κB signaling pathway [74].